Rheumatoid Arthritis Therapeutics Market Driven By Improving Treatment Options For Moderate-To-Severe Rheumatoid Arthritis With Second-Line Therapies
The
global rheumatoid arthritis therapeutics market size is
expected to reach USD 30.4 billion by 2025, according to a new report by Grand
View Research, Inc., expanding at a CAGR of 4.6% during the forecast period.
Some of the key trends driving the market are availability of novel biologics,
increase in potential clinical pipeline candidates, and rise in aging
population. Thus, growing availability and awareness of safer drugs are
projected to escalate rheumatoid arthritis drugs market growth.
Rheumatoid
arthritis affects approximately 1% of the global population. The condition has
different symptoms such as joint pain, swelling, and stiffness, which are
generally accompanied by chronic pain and inability to perform daily
activities. Over a prolonged period, this disorder can hamper a patient’s
mobility and can lead to permanent joint damage. If left untreated, this
disorder can lead to mobility impairment and risk of joint replacement.
Growing
prevalence of the disease, presence of biologics & biosimilars, and
well-defined regulatory guidelines are poised to provide a fillip to the
market. According to the Arthritis Foundation, 64% of the population within the
age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness
regarding disease remittance therapies and rising healthcare expenditure in
developed regions are estimated to promote revenue growth.
Current
treatment for rheumatoid arthritis includes generic pharmaceuticals such as
NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors
and IL-6 antagonists, which are widely used in developed countries due to their
high effectiveness. New product launches such as Infliximab and Adalimumab
biosimilars are anticipated to work in favor of the market. Moreover, Eli
Lilly’s Olumiant and AbbVie’s Upadacitinib are expected to cut down chances of
disease remittance.
Browse full
research report on Rheumatoid Arthritis Therapeutics Market: www.grandviewresearch.com/industry-analysis/rheumatoid-arthritis-therapeutics-market
Further
Key Findings From the Study Suggest:
- North America held 56.6% of the market in 2016
due to rising awareness regarding disease treatment, growing geriatric
population, and high adoption of biopharmaceuticals for treatment
- Due to growing popularity, the
biopharmaceuticals segment is projected to exhibit a CAGR of 8.3% during
the forecast period
- Prescriptions are anticipated to emerge as more
reliable and a preferred sales channel over the same period
- Asia Pacific is the most promising region,
registering a CAGR of 9.5% between 2017 and 2025
- Some of the key players in rheumatoid arthritis
market are AbbVie; Boehringer Ingelheim GmbH; Novartis AG; Regeneron
Pharmaceuticals, Inc.; Pfizer, Inc.; Bristol-Myers Squibb Company; F.
Hoffmann-La Roche Ltd.; UCB S.A.; Johnson & Johnson Services, Inc.;
and Amgen, Inc.
Browse more
reports of this category by Grand View Research: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the rheumatoid arthritis
drugs/therapeutics market on the basis of molecule types, sales channels, and
region:
- Pharmaceuticals
- NSAIDs
- Analgesics
- DMARDs
- Glucocorticoids
- Biopharmaceuticals
- Biologics
- TNF-α
antagonists
- T-cell
inhibitors
- CD20
antigen
- JAK
inhibitors
- anti-IL6
biologics
- Biosimilars
- CD20
antigen
- TNF-α
antagonists
Rheumatoid
Arthritis Therapeutics Sales Channel Outlook (Revenue, USD Million, 2014 -
2025)
- Prescription
- Over-the-Counter
(OTC)
Rheumatoid
Arthritis Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North
America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Asia
Pacific
- Japan
- China
- Latin
America
- Brazil
- Mexico
- Middle East
& Africa
- South
Africa
Access
Press Release By Grand View Research: www.grandviewresearch.com/press-release/global-rheumatoid-arthritis-therapeutics-market
About Grand
View Research:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
Comments
Post a Comment